Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2011 07:30 ET | Source: Zogenix

Zogenix Receives 2011 Drug Delivery Partnerships Innovation Award for SUMAVEL(R) DosePro(TM)

SAN DIEGO, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the...
February 08, 2011 16:32 ET | Source: Zogenix

Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference

SAN DIEGO, Feb. 8, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that Chief Executive Officer Roger L. Hawley, along with Executive Vice President and Chief Financial Officer...
January 06, 2011 07:30 ET | Source: Zogenix

Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom

SAN DIEGO and HAMBURG, Germany, Jan. 6, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") today announced that the Federal Institute for...
December 23, 2010 07:30 ET | Source: Zogenix

Zogenix Announces Partial Exercise of Over-Allotment Option for Initial Public Offering

SAN DIEGO, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today that the underwriters of its recently completed initial public offering of common stock have...
December 13, 2010 07:30 ET | Source: Zogenix

Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM)

SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™...
December 02, 2010 07:30 ET | Source: Zogenix

Zogenix and Desitin Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM)

SAN DIEGO and HAMBURG, Germany, Dec. 2, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved...
November 30, 2010 07:30 ET | Source: Zogenix

Zogenix Announces Completion of Enrollment in ZX002 Phase 3 12-Month Safety Study

SAN DIEGO, Nov. 30, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral,...
November 22, 2010 20:45 ET | Source: Zogenix

Zogenix Announces Pricing of Initial Public Offering

SAN DIEGO, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) announced today the pricing of its initial public offering of 14,000,000 shares of its common stock at $4.00 per...